Systemic treatment strategies for triple-negative breast cancer

Table 3 Response to neoadjuvant platinum based chemotherapy trials in triple-negative breast cancer

Ref.	Yr	No.	Regimen	PCR
Garber et al[20]	2006	28	Cisplatin	21%
Silver et al[21]	2010	28	Cisplatin 3 wk × 4	22%
Byrski et al[22]		12	Cisplatin	83%
2Byrski et al[23]	2009	25	Cisplatin + paclitaxel + GSF	72%
Ryan et al[24]	2009	51	Cisplatin + bevacizumab 3 wk × 4	72%
Frasci et al[25]	2009	74	Cisplatin + epirubicin + paclitaxel wk × 8	65%
Sirohi et al[26]	2008	62	Platinum1 + epirubicin + 5-FU (infusion)	88% (cCR)
Sikov et al[27]	2007	10	Carboplatin 3 wk × 4 + paclitaxel wk × 16	50%
Leone et al[28]	2009	125	Platinum1 + docetaxel 3 wk × 4	29%
			Platinum + docetaxel → AC 3 wk × 4	40%

¹Cisplatin or carboplatin;

²In BRCA1 mutation carriers. AC: Doxorubicin + cyclophosphamide; 5-FU: 5-Fluorouracil; PCR: Pathological complete response; cCR: Clinical complete response; GSF: Granulocyte stimulating factor.